China Insurance Regulator Stresses Thin Profit For Severe Disease Insurance
This article was originally published in PharmAsia News
The China Insurance Regulatory Commission will ensure slim profits for insurance companies via mechanisms such as scientific pricing, supervision fee reductions, and profit-adjustments.
You may also be interested in...
Years after a scathing Indian parliamentary report flagged concerns around regulatory lapses for drug approvals, an expert panel has endorsed the continued marketing of ambrisentan and everolimus in the country. But dronedarone, also featured in the report, is no longer sold by Sanofi in India.